Join us as we extend the conversation from November’s IPO panel to a discussion of some nontraditional paths to market.  Karen Zaderej, CEO of AxoGen, Inc., will share insights from the process of becoming and being a public company through a reverse merger and the pursuit of the BLA (Biologics License Application) path to market in a medtech world.  Additionally, she’ll discuss her passion around maintaining an entrepreneurial culture in a growing company. 

• $45.00 per person
• Space limited
• 6:00 p.m. Networking Reception
• 7:00 p.m. Program: Nontraditional paths to the equity and commercial markets

Our Sponsors: